Latest Content

A leukemia survivor recalls how bonding with other patients helped his hospital stays go by faster and became a key part of his emotional healing.

Learn how nipple-sparing mastectomy, including endoscopic approaches, may help preserve appearance, reduce scarring and support breast cancer recovery.

After 17 and a half years with metastatic primary peritoneal cancer, a former hospital executive explains how an AI health agent helped her after discharge.

Relatives of people with BRCA1 or BRCA2 variants completed genetic testing more often when a navigator reached out directly than when they received a letter.

The FDA approval is based on the phase 3 BRUIN CLL-313 trial, in which 94% of patients responded to Jaypirca compared with 81% who received chemoimmunotherapy.

Giredestrant plus Afinitor lowered the risk of cancer worsening or death by 62% in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer.

Five-year results presented at ASTRO 2026 show a five-week radiation schedule after prostatectomy controls cancer as well as a seven-week course. But serious urinary side effects were more common.

A study of more than 17,000 patients ages 23 to 64, presented at ASTRO 2026, found that only about 28% took endocrine therapy consistently for five years, and people who skipped radiation were more likely to fall off. Here's what to weigh before making that choice.

September brought new options for breast, lung, kidney, bile duct, skin and neuroendocrine cancers, plus a brain tumor scan and easier lung cancer treatment.

Ivonescimab outperformed Keytruda, a new myeloma drug lowered progression risk by 60% and more: the biggest phase 3 cancer results of September 2026.

Breast cancer treatment has changed dramatically since 2021. Here are the key FDA approvals, year by year, and what they mean for patients.

Choosing hospice care brought comfort, support and precious time for one family as they navigated cancer, caregiving and bringing a loved one home.

Learn how to cope with life after cancer treatment with Dr. Eric Bengtsen, a psycho-oncology psychiatrist at Memorial Sloan Kettering Cancer Center.